Home versus in-patient treatment for deep vein thrombosis

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Othieno, Richard ^a   Abu Affan, M ^b   Okpo, E ^b  

^a NHS GRAMPIAN   (United Kingdom)

^b NONE

Author keywords

*Home care services; *Hospitalization; Fibrinolytic agents *therapeutic use ; Heparin *therapeutic use ; Heparin, low molecular weight therapeutic use ; Randomized controlled trials as topic; Recurrence prevention control

Indexed keywords

ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FLUINDIONE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

BLEEDING; BLOOD CLOT; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; COST OF ILLNESS; DATA EXTRACTION; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBASE; HOME CARE; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; IMMOBILIZATION; LEG SWELLING; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; POSTTHROMBOSIS SYNDROME; PUBLICATION; RECURRENT DISEASE; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ULCER; VARICOSIS; VENOUS THROMBOEMBOLISM;

EID: 44949248366     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003076.pub2     Document Type: Review

References (48)

1. Boccalon 2000 {published data only} Boccalon H, Elias A, Chale JJ, Cadene A, Dumoulin A. [Treatment of deep vein thrombosis at home: from theory to medical practice] [French]. Bulletin de l'Academie Nationale de Medecine 1998;182(1):101-15.
2. *Boccalon H, Elias A, Chale JJ, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Archives of Internal Medicine 2000;160(12):1769-73.
3. Chong 2005 {published data only} Chong BH.A randomized, prospective, multicentre study comparing the efficacy, safety and cost of once-daily enoxaparin given at home with unfractionated heparin given in hospital in the treatment of deep-vein thrombosis. Blood 2002;100(11):Abstract 2772.
4. *Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH, ASTH DS Group. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. Journal of Thrombosis & Thrombolysis 2005;19(3):173-81. [MEDLINE: 6813].
5. Daskalopoulos 2005 {published data only} Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D, et al.Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): A prospective randomized trial. European Journal of Vascular & Endovascular Surgery 2005;29(6):638-50. [MEDLINE: 6241].
6. Koopman 1996 {published data only} Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al.Treatment of patients with venous thrombosis with intravenous unfractionated heparin in hospital compared with subcutaneous low-molecular-weight heparin out of hospital. Annals of Hematology 1996;72:A3. [MEDLINE: 6887].
7. *Koopman MMW, Prandoni P, Piovella F Ockelford PA, Brandjes DPM, van der Meer J, et al.Treatment of venous thrombosis with intravenous unfractionated heparin in hospital as compared with subcutaneous lowmolecular weight heparin at home. New England Journal of Medicine 1996;334(11):682-7.
8. van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - an economic evaluation. Thrombosis and Haemostasis 1998;79:259-62.
9. Levine 1996 {published data only} Levine M, Gent M, Hirsch J, Leclerc J, Anderson D, Weitz J, et al.A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. New England Journal of Medicine 1996;334:677-82.
10. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, et al.Economic evaluation of outpatient treatment with low-molecular-weight-heparin for proximal vein thrombosis. Archives of Internal Medicine 1999;159:2298-304.
11. Ramacciotti 2004 {published data only} Ramacciotti E, Araujo GR, Lastoria S, Dietrich F, Maffei FH, Mussi NS. The efficacy and safety of enoxaparin once-daily given partly at home, compared with unfractionated heparin given in the hospital in the treatment of proximal deep-vein thrombosis, a Brazilian multicenter study. Blood 2001;98(11):Abstract 4026.
12. Ramacciotti E, Araujo GR, Lastoria S, Maffei FH, Dietrich F. An open-label, comparative study of the efficacy and safety of an outpatient single daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Blood 2002;11:503a- Absttract 1960.
13. Ramacciotti E, Araujo GR, Lastoria S, Maffei FH, Dietrich-Neto F, CLETRAT Investigators. Efficacy and safety of once-daily Enoxaparin given in the outpatient setting compared with in-hospital unfractionated heparin for treatment of proximal lower limb deep-vein thrombosis. Journal of Thrombosis & Haemostasis 2003;1(Suppl 1):Abstract P1401. [MEDLINE: 6480].
14. *Ramacciotti E, Araujo GR, Lastoria S, Maffei FH, Karaoglan DM, Michaelis W, Sandri JL, Dietrich-Neto F. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thrombosis Research 2004;114(3):149-53. [MEDLINE: 5944].
15. Backman 2004 Backman K, Carlsson P, Kentson M, Hansen S, Engquist L, Hallert C. Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment. Scandinavian Journal of Primary Health Care 2004;22(1):44-9. [MEDLINE: RCT].
16. Belcaro 1999 Belcaro G, Nicolaides AN, Cesarone MR, Laurora G, De Sanctis MT, Incandela L, et al.Comparison of low molecular weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology 1999;50(10):781-7.
17. Blattler 1998 Blattler W, Borer W, Linder C. Outpatient and conventional treatment of acute deep vein thrombosis evaluated in a controlled single-centre study. Phlebologie 1998;51:41-6. [MEDLINE: RCT].
18. Buller 2004 Buller HR, The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with Fondaparinux (Arixtra(R)): The MATISSE Trials. Blood 2004; Vol. 104, issue 11:Abstract 705. [MEDLINE: 6728].
19. Buller 2005 Buller H. Initial outpatient treatment of venous thromboembolism with Fondaparinux (Arixtra® ): The MATISSE trials. Journal of Thrombosis & Haemostasis. 2005; Vol. 3, issue 1.
20. Conner 1999 Conner C. Innohep User's meeting, Windsor. Data on file 1999.
21. Fitzmaurice 2000 *Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerised decision support and near-patient testing: a randomised, controlled trial. Archives of Internal Medicine 2000;160(15):2343-8.
22. Frank 1998 Frank D, Blattler W. [Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects]. [German]. Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine 1998;128(36):1328-33.
23. Goldhaber 1998 Goldhaber SZ, Morrison RB, Diran LL, Creager MA, Lee TH. Abbreviated hospitalisation for deep vein thrombosis with the use of ardeparin. Archives of Internal Medicine 1998;158(21):2325-8.
24. Grau 1998 Grau E, Real E, Pastor E, Viciano V, Aguilo J. Home treatment of deep vein thrombosis: a two-years experience of a single institution. Haematologica 1998;83(5):438-41.
25. Grau 2001 Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, et al.Home treatment of deep vein thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. American Journal of Haematology 2001;67(1):10-4.
26. Green 1998 Green ES, Rhodes S, Bond S, Thomson S, Troughton AH. Outpatient treatment of deep vein thrombosis using low molecular weight heparin. British Journal of Haematology 1998;101(Suppl. 1):Abstract 234.
27. Hull 2000 Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al.Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine 2000;160(14):2208-15. [MEDLINE: 4751].
28. Hull 2002 Hull RD, Pineo GF, Mah AF. Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post-treatment period for patients randomized to long-term low-molecular-weight heparin (LMWH) versus warfarin sodium. Blood 2002; Vol. 100, issue 11:Abstract 1951. [MEDLINE: 5839].
29. Lindmarker 1996 Lindmarker P, Holstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. Journal of Internal Medicine 1996;240(6):395-401.
30. Miles 1998 Miles J, O'Shaugnessey D, Wimperis J. Outpatient management of DVT in the United Kingdom. Presentation to American Thoracic Society. 1998.
31. O'Shaugnessy 1998 O'Shaughnessy DF, Tovey C, Miller ALC, O'Neill V, Rana PS, Akbar S, et al.Outpatient management of deep vein thrombosis. Journal of Accident & Emergency Medicine 1998;15(5):292-3.
32. Pineo 2003 Pineo GF, Hull RD, Mah AF, Lite I. Does rebound exist? A comparison of venous thromboembolic event rates in the post-treatment period for patients randomized to long-term low-molecular-weight heparin vs. warfarin sodium. Journal of Thrombosis & Haemostasis 2003; Vol. 1, issue Suppl 1:Abstract P1882. [MEDLINE: 6510].
33. Rymes 2002 Rymes NL, Lester W, Connor C, Chakrabati S, Fegan CD. Outpatient management of DVT using LMWH and a hospital outreach service. Clinical & Laboratory Haematology 2002;24(3):165-70.
34. Ting 1998 Ting SBN, Ziegenbein RW, Gan TE, Catalano JV, Monagle P, Silvers J, et al.Dalteparin for deep vein thrombosis: a hospital-in-the-home program. Medical Journal of Australia 1998;168(6):272-6.
35. Wells 1998 Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, et al.Expanding eligibility for outpatient treatment of deep vein thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Archives of Internal Medicine 1998;158(16):1809-12.
36. White 1989 *White RH, McCurdy SA, von Marensdorff H, Woodruff DEJ, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomised, prospective study. Annals of Internal Medicine 1989;111(9):730-7.
37. Wimperis 1998 Wimperis JZ, Pout G, Dilks G, Wilson P, Clarke J, Jenkins P, et al.Significant bed savings resulting from outpatient management of deep vein thrombosis with low molecular weight heparin. British Journal of Haematology 1998;101(Suppl. 1):Abstract 231.
38. Bakker 1988 Bakker M, Dekker PJ, Knot EA, van Bergen PF, Jonker JJ. Home treatment for deep venous thrombosis with low molecular weight heparin [letter]. Lancet 1988;2:1142.
39. Baron 1999 Baron RM, Goldhaber SZ. Deep venous thrombosis: early discharge strategies and outpatient management. Journal of Thrombosis and Thrombolysis 1999;7(2):113-22. [MEDLINE: 99294923].
40. de Lissovoy 2001 de Lissovoy G, Yusen RD, Spiro TE, Krupski WC, Champion AH, Sorensen SV. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine 2001;160(20):3160-5.
41. Griffin 1996 Griffin J. Deep venous thrombosis and pulmonary embolism. London: Office of Health Economics, 1996.
42. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
43. Leizorovicz 1994 Leizorovicz A, Simmoneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weght heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. British Medical Journal 1994;309:299-304.
44. Lensing 1995 Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Archives of Internal Medicine 1995;155(6):601-7.
45. O'Brien 1999 O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, et al.Economic evaluation of outpatient treatment with low-lolecular-leight-heparin for proximal vein thrombosis. Archives of Internal Medicine 1999;159:2298-304.
46. van den Belt 1998 van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - an economic evaluation. Thrombosis and Haemostasis 1998;79:259-62.
47. van Dongen 2004 van Dongen CJJ, van den Belt AGM, Prins MH, Lensing AWA. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD001100. DOI: 10.1002/14651858.CD001100.pub2.Art. No.: CD001100. DOI:10.1002/14651858. CD001100.pub2.
48. Schraibman 2001 Schraibman IG, Milne AA, Royle EM. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD003076. DOI: 10.1002/14651858.CD003076.Art. No.: CD003076. DOI: 10.1002/14651858.CD003076. pub2.